NCT01036022 - Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

September 15, 2009

Primary Completion Date

January 10, 2013

Study Completion Date

January 10, 2013

Conditions

Colitis, Ulcerative

Interventions

DRUG

GSK1399686

Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.

Trial Locations (26)

1200

GSK Investigational Site, Brussels

1478

GSK Investigational Site, Lørenskog

2820

GSK Investigational Site, Bonheiden

3116

GSK Investigational Site, Tønsberg

9000

GSK Investigational Site, Ghent

10117

GSK Investigational Site, Berlin

20148

GSK Investigational Site, Hamburg

20246

GSK Investigational Site, Hamburg

24105

GSK Investigational Site, Kiel

30625

GSK Investigational Site, Hanover

48149

GSK Investigational Site, Münster

67067

GSK Investigational Site, Ludwigshafen am Rhein

T6G 2C8

GSK Investigational Site, Edmonton

K7L 5G2

GSK Investigational Site, Kingston

N6A 4G5

GSK Investigational Site, London

L4L 4Y7

GSK Investigational Site, Vaughan

G1S 4L8

GSK Investigational Site, Québec

01307

GSK Investigational Site, Dresden

04129

GSK Investigational Site, Leipzig

07747

GSK Investigational Site, Jena

0514

GSK Investigational Site, Oslo

N-0456

GSK Investigational Site, Oslo

SE-416 85

GSK Investigational Site, Gothenburg

SE-221 85

GSK Investigational Site, Lund

SE-111 86

GSK Investigational Site, Stockholm

SE-171 76

GSK Investigational Site, Stockholm